CNBC's Michael Bloom contributed to this report.
#SAFE LIFE DEFENSE DRIVERS#
"While we don't see any significant upside drivers apart from continued expansion of the Enhanze portfolio and commercial execution by partners in the near-term, we still think Halozyme remains defensive against future downturns in the biotech market," he wrote. Morgan Stanley's $50 price target suggests shares could rally 26% from Thursday's close. Heavy fighting has been going on in southern Ukraine near Kherson and also recently in the northeast near Kharkiv as defence forces mounted a surprise. He particularly called attention to its Enhanze drug delivery technology platform that's utilized by top biopharmaceutical companies like Pfizer and Bristol-Myers Squibb. Safe Life Defense - Latest Emails, Sales & Deals 5 Reasons Shop Armor Now & Pay Later 24 HR Warning Shop ARMOR ON SALE 12 Tips for Parents: BACKPACK. Web traffic rankings are better than the industry average. Since Safe Life Defense was founded, the company has grown faster than the industry average.
Revenue growth is more steady than the industry average. The number of employees is growing faster than the industry average. More specifically, Galler sees value in Halozyme's diversified revenue streams. Safe Life Defense has a strong market share in their industry. Analyst Andrew Galler initiated coverage of Halozyme Therapeutics with an overweight rating and a $50 price target, calling the company a "safe port in a storm." "Given the macro backdrop, we view Halozyme as the most defensive name in our coverage given its established royalty business, long-term potential for growth, and diversified base business via its acquisition of Antares," he wrote. Morgan Stanley says investors looking for a hideout in this volatile market should consider putting their money in this lesser known biotechnology stock.
0 kommentar(er)
